ABUS vs DASH
Arbutus Biopharma Corp (ABUS) versus DoorDash, Inc. Class A Common Stock (DASH) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Not investment advice. Open the ABUS and DASH stock pages for the full models.
Not investment advice.